Image pharmaphorum Editor News Tech firms treat young, fit patients, instead of those in ne... The UK’s top GP is due to refute accusations that doctors are ‘technophobic dinosaurs’. News Lilly unveils promising data from dual-action diabetes drug Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial results announced this week. News Recardio ceases UK drug trials, blaming Brexit Medical research firm Recardio has ceased all of its drug trials in the UK over concerns about Brexit. News Roche poised for push into haemophilia market Roche is aiming to shore up its place in the haemophilia drug market, with Hemlibra (emicizumab) on the brink of regulatory approval for expanded use. Load more results
News Tech firms treat young, fit patients, instead of those in ne... The UK’s top GP is due to refute accusations that doctors are ‘technophobic dinosaurs’.
News Lilly unveils promising data from dual-action diabetes drug Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial results announced this week.
News Recardio ceases UK drug trials, blaming Brexit Medical research firm Recardio has ceased all of its drug trials in the UK over concerns about Brexit.
News Roche poised for push into haemophilia market Roche is aiming to shore up its place in the haemophilia drug market, with Hemlibra (emicizumab) on the brink of regulatory approval for expanded use.
News FDA starts review of Regeneron's drug for rare disease FOP Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
